Ischemic stroke is the third deadliest disease after heart disease and tumor, and the first disease that causes disability in adults. In response to the development of medical technology, the Department of Neurology has established the Cerebrovascular Disease Group and has been carrying out new technologies and treatments, mainly including the following: 1.Whole brain angiography This technique can detect vascular lesions that cannot be detected by CT and MRI, such as the site and length of stenosis, cerebral aneurysm, cerebral arteriovenous malformation, and the site of vascular occlusion, providing an accurate basis for interventional treatment. 2.Ultra-early interventional thrombolysis and thrombectomy for acute cerebral infarction This technology can make the occluded blood vessels of cerebral infarction patients reopen within a short period of time, avoiding the adverse consequences of death or aphasia and hemiplegia that may still occur in patients with cerebral infarction after hospitalization in the past, and the postoperative hospitalization time of patients can be shortened to less than 3 days; this technology requires patients to arrive at the hospital within 6 hours after the onset of the disease, the earlier the better. 3.Carotid artery stenosis is an important risk factor and cause of long-term dizziness and headache and cerebral infarction. Stent-assisted angioplasty can significantly improve patients’ discomfort and greatly reduce the incidence of cerebral infarction. The above technique is fundamentally different from the traditional drug treatment, and is a new technique to obtain the maximum therapeutic effect with the minimum therapeutic trauma. Indications: 1.Age below 80 years old, without serious heart, liver and kidney dysfunction. 2.The onset of the carotid system is within 6 hours, and the vertebral low artery system is within 12 hours. 3, There was obvious neurological dysfunction and it was gradually aggravated; there was no hypodense foci on CT and cerebral hemorrhage or other obvious intracranial lesions were excluded. 4.No bleeding tendency, and the coagulation function is basically normal. 5.Family members signed consent. Absolute contraindications: 1.Simple sensory disorder or ataxia. 2, clinical symptoms improve quickly. 3.With active intracranial hemorrhage. 4.Having bleeding quality or bleeding disorders 5.Intracranial aneurysm, arteriovenous malformation, intracranial tumor or suspected subarachnoid hemorrhage. 6.History of hemorrhage.